Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF) — De Clercq Erik (2016) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
Shared by
De Clercq Erik
KU Leuven
Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
Article
2016
en
Related publications
Article
2017
Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections
De Clercq Erik
Article
2018
Pharmacokinetics of Oral Tenofovir Disoproxil Fumarate in Pregnancy and Lactation: A Systematic Review
Marieke Bierhoff
,
Elise J. Smolders
,
Joel Tärning
,
David M. Burger
,
René Spijker
,
Marcus J. Rijken
,
Authors
De Clercq Erik
KU Leuven
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Chaisiri Angkurawaranon
,
Rose McGready
,
Sir Nicholas White
,
François Nosten
,
Michèle van Vugt
Antiviral Therapy
Article
2001
Evaluation of the mechanism(s) of secretion of the conversion products of tenofovir disoproxil fumarate out of Caco-2 cells
J.F. Van Gelder
,
S. Deferme
,
Nico Vermeulen
,
Raf Mols
,
Guy Van den Mooter
,
De Clercq Erik
,
Renaat Kinget
,
Patrick Augustijns
Article
2001
Evidence for multidrug resistance-associated proteins related efflux of the metabolites of tenofovir disoproxil fumarate in Caco-2 monolayers
J. Van Gelder
,
S. Deferme
,
Nico Vermeulen
,
Raf Mols
,
Guy Van den Mooter
,
De Clercq Erik
,
Lieve Naesens
,
Renaat Kinget
,
Patrick Augustijns
Article
2002
Intestinal Absorption Enhancement of the Ester Prodrug Tenofovir Disoproxil Fumarate through Modulation of the Biochemical Barrier by Defined Ester Mixtures
J. Van Gelder
,
S. Deferme
,
Lieve Naesens
,
De Clercq Erik
,
Guy Van den Mooter
,
Renaat Kinget
,
Patrick Augustijns
Discussion(0)
No comments yet. Be the first to comment.